Report of Foreign Issuer (6-k)
January 03 2018 - 8:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of the
Securities
Exchange Act of 1934
For
the month of January 2018
Commission
File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation
of registrant’s name into English)
8
Hasatat St.
Modiin
Israel
7178106
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F [X] Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
[ ] No [X]
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
EXPLANATORY
NOTE
Attached
hereto and incorporated by reference herein is the registrant’s press release issued on January 3, 2018, titled “VBL
Therapeutics Announces the Appointments of Susan Kelley and David Hastings to its Board of Directors. This Report of Foreign Private
Issuer on Form 6-K shall be incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-207250),
filed with the Securities and Exchange Commission (the “SEC”) on October 2, 2015 and registration statement on Form
F-3 (File No. 333-222138) filed on December 18, 2017, to the extent not superseded by information subsequently filed or furnished
(to the extent the Company expressly states that it incorporates such furnished information by reference) by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
VASCULAR
BIOGENICS LTD.
|
|
|
Date:
January 3, 2018
|
By:
|
/s/
Dror Harats
|
|
Name:
|
Dror
Harats
|
|
Title:
|
Chief
Executive Officer
|
VBL
THERAPEUTICS ANNOUNCES THE APPOINTMENTS OF SUSAN KELLEY
AND DAVID HASTINGS TO ITS BOARD OF DIRECTORS
Senior
pharmaceutical executives with extensive experience in immuno-oncology, drug development,
commercializing oncology medications and finance
TEL
AVIV, Israel, Jan. 3, 2018 - VBL Therapeutics (NASDAQ:VBLT), today announced the appointments of both David Hastings and Susan
Kelley, M.D. to its Board of Directors.
Susan
L. Kelley, M.D. is an oncologist with extensive experience in drug development and commercialization. Susan Kelley received her
M.D. from Duke University School of Medicine and completed oncology training at the Dana-Farber Cancer Institute in Boston. She
was also a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine Dr. Kelley joined the pharmaceutical
industry and worked with Bristol-Myers Squibb in Oncology and Immunology drug development from 1987 to 2001. From 2001 to 2008,
Dr. Kelley worked with Bayer Healthcare Pharmaceuticals as Vice President, Global Clinical Development and Therapeutic Area Head
– Oncology. She led the Bayer team responsible for the development and worldwide regulatory approval of Nexavar (sorafenib)
in kidney cancer and liver cancer, and was also responsible for clinical development of the early pipeline drug candidates. From
2008 to 2011, she was Chief Medical Officer of the Multiple Myeloma Research Consortium, where her leadership responsibilities
included the strategic design and management of clinical trials conducted by leading myeloma clinical research centers in North
America. Dr. Kelley served as a member of the Board of Directors of Alchemia from 2013-2015, and Cerulean Pharma from 2014-2017.
She is currently a Director at ArQule, Immune Design, and Daré Bioscience, all publicly-traded, US-based biotechnology
companies.
David
Hastings has more than 18 years of finance, accounting and operations experience in the bio-pharmaceutical industry. He was the
Executive Vice President and Chief Financial Officer at Incyte from October 2003 until 2014. Recently he was the Chief Financial
Officer of Unilife Corporation. From February 2000 to September 2003 Mr. Hastings served as Vice President, Chief Financial Officer
and Treasurer of ArQule Inc. Prior to his employment with ArQule, Mr. Hastings was Vice President and Corporate Controller at
Genzyme Inc., and Director of Finance at Sepracor. David Hastings received his B.A. in Economics at the University of Vermont.
He is a member of the Board Director of SCYNEXIS, Inc. and chairs its Audit Committee.
“We
expect Susan and David to be important additions to the VBL Therapeutics Board of Directors,” said Ben Shapiro, M.D., Chairman
of VBL Therapeutics, “David brings a wealth of financial and business experience to our existing board and Susan’s
experience with the FDA approval process will be invaluable to us as we prepare to bring VB-111 to the market in the coming months.
We look forward to the guidance both David and Susan will provide us as we anticipate top line results from our Phase 3 GLOBE
pivotal trial in recurrent glioblastoma in the first quarter.”
“VBL’s
pipeline of novel oncology biologics is positioned to make a large impact on the lives of patients and on their families. This
is most clear in the case of glioblastoma, where VB-111 has potential to be a first-in-class treatment for what has been, to date,
an essentially incurable form of cancer. I look forward to working with VBL to bring life-changing new treatments to patients
as soon as possible,” stated Dr. Kelley.
Mr.
Hastings commented, “VBL Therapeutics is building upon a successful 2017 by looking to start the new year very strong with
several important upcoming milestones on the horizon. By joining the VBL team at such an exciting juncture I have the opportunity
to assist with guiding the company’s bright future.”
About
VBL
Vascular
Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development
and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is
a first-in-class, targeted anti-cancer gene-therapy biologic with broad potential to treat a wide range of solid tumors. In October
2017, VBL opened its new gene therapy manufacturing plant in Modiin, Israel. This plant will be the commercial facility for production
of the Company’s lead product candidate. The Modiin facility is the first commercial-scale gene therapy manufacturing facility
in Israel and currently one of the largest gene-therapy designated ones in the world (20,000 sq. ft.).
Forward
Looking Statements
This
press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “goal,” “intend,” “look forward to”, “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would”
and similar expressions. These forward-looking statements include, but are not limited to, statements regarding VB-111, including
its clinical development, therapeutic potential and clinical results, including the expected timing of clinical results and the
initiation of clinical trials. These forward-looking statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein
include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals,
and the risk that historical clinical trial results may not be predictive of future trial results. In particular, results from
our pivotal Phase 3 clinical trial of VB-111 in rGBM may not support approval of VB-111 for marketing in the United States, notwithstanding
the positive results seen in prior clinical experience. A further list and description of these risks, uncertainties and other
risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our
annual report on Form 20-F for the year ended December 31, 2016. Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation
to update or revise the information contained in this press release, whether as a result of new information, future events or
circumstances or otherwise.
INVESTOR
CONTACT:
Michael
Rice
LifeSci
Advisors
mrice@lifesciadvisors.com
(646)
597-6979
MEDIA
CONTACT:
Matt
Middleman, M.D.
LifeSci
Public Relations
matt@lifescipublicrelations.com
(646)
627-8384
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024